Last reviewed · How we verify
Efficacy of Botox subdermally at Week 24
Efficacy of Botox subdermally at Week 24 is a Small molecule drug developed by ASIS Corporation. It is currently in Phase 1 development. Also known as: Botox (onabotulinumtoxinA).
At a glance
| Generic name | Efficacy of Botox subdermally at Week 24 |
|---|---|
| Also known as | Botox (onabotulinumtoxinA) |
| Sponsor | ASIS Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efficacy of Botox subdermally at Week 24 CI brief — competitive landscape report
- Efficacy of Botox subdermally at Week 24 updates RSS · CI watch RSS
- ASIS Corporation portfolio CI
Frequently asked questions about Efficacy of Botox subdermally at Week 24
What is Efficacy of Botox subdermally at Week 24?
Efficacy of Botox subdermally at Week 24 is a Small molecule drug developed by ASIS Corporation.
Who makes Efficacy of Botox subdermally at Week 24?
Efficacy of Botox subdermally at Week 24 is developed by ASIS Corporation (see full ASIS Corporation pipeline at /company/asis-corporation).
Is Efficacy of Botox subdermally at Week 24 also known as anything else?
Efficacy of Botox subdermally at Week 24 is also known as Botox (onabotulinumtoxinA).
What development phase is Efficacy of Botox subdermally at Week 24 in?
Efficacy of Botox subdermally at Week 24 is in Phase 1.
Related
- Manufacturer: ASIS Corporation — full pipeline
- Also known as: Botox (onabotulinumtoxinA)
- Compare: Efficacy of Botox subdermally at Week 24 vs similar drugs
- Pricing: Efficacy of Botox subdermally at Week 24 cost, discount & access